BRKR Bruker Corporation

XNAS 58.23 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

BRKR $58.23 —
Key stats
$58.23
Pre-market $58.51 +0.48%
52-Week Range
$32.37 – $66.98
YTD
+21.04%
IV Rank (30D)
87.52
Straddle Price
$9.05
P/C Vol Ratio
0.62
Market Cap
$8.8B
Open
$57.79
Day Range
$57.27 – $58.30
Volume
2,333,461
Prev Close
$57.59
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.13%
Beta vs SPY1.05
Cost of Equity (CAPM)10.89% (VRP-adj)
WACC10.00%
Volatility Risk Premium+22.9pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.3%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$0.1B
Return on Equity (TTM)-4.5%
Book / Price28.2%
Gross Margin (TTM)45.3%
FCF Margin (TTM)1.9%
Debt / Equity0.67
Quality Score0/6 — cyclical/struggling (5y DCF)
SMA 50$58.71 (Market Anchor value)
SMA 20 / Bollinger Mid$59.16
Bollinger Width / SMA2037.3% (drives anchor stability)
Net Debt$1.5B
Market Cap$9B
Peers used for multiples: AMAT, ASML, CBT, ENTG, LRCX, NVDA, Q, VECO
60-Day Conviction
77%
20-Day Fair Value
≈ by Nov 24, 2026
$59.56
α +2.3% rank 87%
conviction
93%
40-Day Fair Value
≈ by Dec 23, 2026
$60.45
α +3.8% rank 89%
conviction
94%
60-Day Fair Value
≈ by Jan 21, 2027
$59.86
α +2.8% rank 87%
conviction
77%
MethodImplied PriceWeightDetail
DCF $-4.07 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 38.8× · 7 peers
Peer EV/EBITDA $56.78 16% median 25.5× · 7 peers
Peer P/B $76.61 21% median 4.7× · 7 peers
Peer P/S $138.39 21% median 5.9× · 7 peers
Market Anchor (SMA50) $58.71 0% stability 0% (BB-width)
Options Expected (B-L 30d) $56.71 43% 16 strikes · skew +0.17
As of 2026-10-26 · updated
About
Industry (SIC)
LABORATORY ANALYTICAL INSTRUMENTS (3826) · industry map
Exchange
XNAS
Market Cap
$8.8B
Employees
11,085
List Date
2000-08-04
CIK
0001109354
Next Earnings
2026-11-04 (Pre-Market)
EPS Forecast
$0.42 (4 est.)
Headquarters
Billerica, MA
Homepage
https://www.bruker.com

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan8.59%-17.77%1.52%-1.09%-1.12%-7.94%-2.97%
Feb5.07%4.69%-3.42%19.23%-16.73%-8.32%0.09%
Mar2.83%-7.69%16.87%6.35%-10.69%-9.27%-0.27%
Apr5.55%-11.54%1.40%-16.06%-0.79%1.75%-3.28%
May1.15%7.74%-12.03%-17.11%-6.73%60.07%5.52%
Jun10.07%2.20%4.20%-1.09%12.17%2.98%5.09%
Jul7.49%7.88%-5.51%9.91%-8.28%1.83%2.22%
Aug7.04%-18.89%-6.51%-1.67%-10.56%-9.80%-6.73%
Sep-12.61%-5.74%-5.52%5.08%-2.23%15.56%-0.91%
Oct2.71%13.76%-8.32%-15.20%12.15%-5.99%*-0.15%
Nov-0.28%7.05%14.17%-2.26%26.09%--8.95%
Dec3.58%0.99%11.23%0.43%-1.57%--2.93%
Total47.07%-21.48%3.50%-18.41%-14.79%28.16%4.01%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $58.91
SMA 50: $58.73
SMA 200: $50.05
Current: $58.23
EMA 12: $57.66
EMA 26: $58.35
MACD: -0.6930 | Signal: -0.0357
BEARISH
ADX (14): 16.70
RANGE
+DI: 20.05
−DI: 15.18

Momentum Oscillators

RSI (14): 49.57
NEUTRAL
Stoch %K: 36.06
Stoch %D: 31.01
Williams %R: -44.23

Volume & Volatility

BB Upper: $65.17
BB Lower: $52.65
NEUTRAL
OBV: -23,802,513
Vol SMA 20: 2,171,234
Vol ROC: 25.05%
ATR: $2.92
True Range: $1.02
HV 20: 43.9%
HV 30: 53.5%
HV 60: 71.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

BRKR Stock Analysis Report

Executive Summary

Overall Assessment: BULLISH | Confidence Level: 7/10

BRKR presents a cautiously optimistic outlook supported by positive technical momentum and favorable sector tailwinds, though several warning signals warrant careful position management. The stock is trading above all major moving averages with bullish MACD divergence, while the broader life sciences/analytical instrumentation sector benefits from strong secular growth trends in genomics, mass spectrometry, and precision medicine markets. However, elevated volatility (57% annualized), weak trend strength (ADX 20.61), and concerning volume deterioration present execution risks.

Key Drivers:

  • Positive: Strong moving average alignment, bullish MACD histogram (1.22), sector growth catalysts
  • Risks: Weak ADX trend confirmation, declining volume (-22.67%), high IV premium (41.7%), low correlation (0.29) to market moves

Investment Thesis: BRKR benefits from structural tailwinds in life sciences instrumentation markets, with technical positioning suggesting near-term upside momentum. However, the weak trend strength and volume contraction suggest this rally may lack institutional conviction, requiring confirmation through improved volume and clearer trend establishment before committing significant capital.

Recent News Sentiment Impact: Positive macro-level sentiment regarding end-market growth (genomics, mass spectrometry, metabolomics, digital pathology). These are industry-wide positive catalysts rather than BRKR-specific news, providing sector support but lacking direct company catalysts for price discovery.

Technical Analysis

Trend Direction

Short-term (1-4 weeks): BULLISH

  • Price ($61.94) trades 3.5% above SMA20 ($59.82) and 5.2% above SMA50 ($58.88)
  • EMA12 ($62.01) > EMA26 ($60.37) with positive differential of $1.64
  • Clear uptrend structure with higher lows establishing

Medium-term (1-3 months): BULLISH

  • Price trades 25.8% above SMA200 ($49.22) — significant distance indicates sustained uptrend
  • EMA positioning supports bullish bias
  • However, ADX (20.61) signals weak trend strength — caution on sustainability

Long-term (3-12 months): NEUTRAL-TO-BULLISH

  • Strong gap from 200-day average suggests structural shift in sentiment
  • Sector dynamics (genomics/mass spec market growth) support longer-term thesis
  • Insufficient trend confirmation to declare sustained uptrend

Support/Resistance Levels

| Level | Type | Significance | |-------|------|--------------| | $67.55 | Resistance (Bollinger Upper Band) | Immediate overbought threshold; ~9% upside | | $62.01 | Support (EMA12) | Dynamic support; short-term momentum anchor | | $59.82 | Support (SMA20) | Medium-term trend line; recent trading zone | | $58.88 | Support (SMA50) | 50-day average; key support if consolidation occurs | | $52.09 | Support (Bollinger Lower Band) | Historical support; 16% downside to major defense | | $49.22 | Support (SMA200) | Long-term trend foundation; -20.5% from current |

Momentum Signals

RSI (14): 53.98 — NEUTRAL

  • Positioned in neutral zone (30-70 range)
  • Neither overbought nor oversold
  • Room to run in either direction without extreme technical extremes
  • Suggests current rally not yet "stretched" from momentum perspective

MACD: BULLISH CROSSOVER SIGNAL

  • MACD Line (1.64) significantly above Signal Line (0.42)
  • Histogram (1.22) strongly positive and widening
  • Classic bullish momentum setup
  • Suggests accelerating upside momentum with recent positive divergence
  • Risk: If histogram begins contracting, early warning of momentum exhaustion

Stochastic Oscillators: OVERBOUGHT WARNING

  • Stochastic %K (82.48) and %D (87.26) both in overbought territory (>80)
  • This contradicts neutral RSI reading — suggests short-term momentum is stretched
  • Williams %R (-32.65) shows mixed signal (neutral zone, -50 to 0)
  • Interpretation: Short-term pullback risk likely before further upside; potential mean-reversion opportunity into Bollinger Bands middle ($59.82)

Bollinger Bands: NEUTRAL-TO-BULLISH

  • Price ($61.94) positioned between middle ($59.82) and upper band ($67.55)
  • Width (25.85) suggests moderate volatility expansion from compression
  • Not squeezed (which would suggest breakout pending)
  • Price trending toward upper band suggests potential resistance test
  • Signal: Room to move higher but band width not extreme

Volume Analysis — CRITICAL CONCERN

Volume Rate of Change: -22.67% (BEARISH DIVERGENCE)

  • Volume declining significantly relative to 20-day average
  • Major Red Flag: Volume should increase on breakouts and rallies; declining volume suggests:
    • Lack of institutional conviction behind the rally
    • Potential exhaustion of retail/algorithmic buying interest
    • Weaker structural support for further advances

On-Balance Volume: -34,682,003.56 (NEGATIVE)

  • Cumulative OBV significantly negative
  • Indicates selling volume has exceeded buying volume over analyzed period
  • Conflict with Price Action: Price rising while OBV declining = classic divergence warning
  • Suggests rally may not be backed by substantial accumulation

Volume SMA 20: 2,309,886

  • Current volume tracking below average
  • Confirms volume contraction narrative

Assessment: The volume deterioration is perhaps the most concerning technical indicator. While MACD and moving averages appear bullish, declining volume suggests this rally lacks follow-through buying. This is a critical conflict requiring close monitoring.

News & Sentiment Analysis

Recent Headlines Summary

Positive Sector Themes (All Headlines):

  1. Digital Pathology & AI Microscopy (Sept 23, 2026): Market advances through AI-powered image analysis in semiconductor inspection and pathology — directly relevant to BRKR's analytical instrumentation portfolio

  2. Metabolomics Growth (Sept 22, 2026): $9.01B market by 2035 driven by precision medicine and biomarker discovery — BRKR exposure through mass spectrometry and analytical solutions

  3. Mass Spectrometry Market (July 17, 2026): USD 14.09B by 2035 — core end-market for BRKR instrumentation; this is BRKR's sweet spot

  4. Spatial Genomics & Transcriptomics (June 30, 2026): USD 1.90B market, 12.23% CAGR through 2035 — precision medicine trend supporting analytical demand

  5. Omics-Based Clinical Trials (April 24, 2026): $47.78B market opportunity — large TAM driving R&D spending in biopharma/CRO sectors (BRKR customer base)

  6. Silver/Macro Divergence (Jan 13, 2026): Soft CPI, negative market move — dated headline, likely outdated relative to current analysis

Sentiment Assessment: POSITIVE (85% positive, 15% neutral/negative)

  • 5 of 6 recent headlines are industry-positive and relevant to BRKR's end markets
  • Sentiment is macro-positive (sector/market growth) rather than company-specific (no BRKR earnings, partnerships, or product launch announcements)
  • Suggests tailwinds are structural, not event-driven

Catalyst Identification

Immediate/Near-term (0-4 weeks):

  • No company-specific catalysts identified in news
  • Continued sector momentum from genomics/mass spec growth narrative

Medium-term (1-3 months):

  • Earnings Release (Unknown date): Critical catalyst; no earnings data provided — this is a data gap
  • Product Announcements: Life sciences instrumentation typically announces new capabilities in mass spec, imaging, genomics solutions
  • M&A Activity: Consolidation in analytical instruments sector could affect BRKR

Long-term (3-12 months):

  • End-Market Growth Realization: Genomics/precision medicine market expansion materializing in customer spending
  • Regulatory/FDA Approvals: For diagnostic applications using BRKR instrumentation
  • Technology Transitions: Shift to
Generated
News
All BRKR news →
Earnings History
17 of 20 under expected move
Avg Expected Move
9.40%
Avg Actual Move
5.03%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-01-11 Pre-Market 14.16% 0.27% 0.02x Within
2021-11-01 Pre-Market 6.04% 1.15% 0.19x Within
2022-01-10 Pre-Market 17.33% 0.71% 0.04x Within
2022-05-04 Pre-Market 6.99% 6.26% 0.90x Within
2022-11-03 Pre-Market 5.48% 5.11% 0.93x Within
2023-01-09 Pre-Market 4.30% 2.82% 0.66x Within
2023-05-04 Pre-Market 7.89% 1.68% 0.21x Within
2023-08-03 Pre-Market 8.17% 4.83% 0.59x Within
2023-11-02 Pre-Market 8.12% 1.05% 0.13x Within
2024-01-08 Pre-Market 5.73% 4.48% 0.78x Within
2024-05-02 Pre-Market 6.49% 11.31% 1.74x Exceeded
2024-08-06 Pre-Market 11.06% 2.17% 0.20x Within
2024-11-05 Pre-Market 10.87% 3.35% 0.31x Within
2025-01-13 After-Close 4.88% 2.68% 0.55x Within
2025-05-07 Pre-Market 11.34% 3.32% 0.29x Within
2025-07-21 Pre-Market 13.38% 12.12% 0.91x Within
2025-11-03 Pre-Market 14.77% 0.59% 0.04x Within
2026-02-12 Pre-Market 9.49% 11.60% 1.22x Exceeded
2026-05-06 After-Close 6.80% 3.38% 0.50x Within
2026-08-04 Pre-Market 14.69% 21.79% 1.48x Exceeded

Earnings calendar: this week’s reports with expected vs actual moves →

BRKR Options Activity & IV Rank

BRKR IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 69.9%
7-DTE IV: —
Expected Move: $9.05
7-DTE Move: $9.05
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 78
Put Volume: 48
P/C Volume: 0.615
BULLISH
Call OI: 1,100
Put OI: 82
P/C OI: 0.075
Total OI: 1,182

ATM Options Pricing

ATM Call: $5.00
ATM Put: $4.05
Call %: 8.6%
Put %: 7.0%

Chain Summary

Chain Volume: 639
Chain OI: 6,653
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 76th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
76%
vs own history
GEX tilt
+0.73
OI-weighted, today
Vanna tilt
+0.84
δ-sensitivity to IV
Charm tilt
-0.87
δ-decay vs time
Vanna tilt +0.84: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.87: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 20 ATM contracts, 2k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 74.4% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)87.5HighOct 26
Straddle Price (30 DTE)$9.05Oct 26
Beta Analysis

Risk Metrics

Beta: 1.3862
Alpha: 38.26%
Correlation: 0.3131
R-Squared: 9.8%
Stock Volatility: 56.4%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own BRKR
5 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Viking Global Hedge fund
Andreas Halvorsen
$53.8M
0.15%
#74 of 90new13F
Glenview Capital Hedge fund
Larry Robbins
$15.2M
0.30%
#36 of 42new13F
Citadel Hedge fund
Ken Griffin
$10.7M
0.01%
#1538 of 6285-9.0%13F
Bridgewater Associates Hedge fund
Ray Dalio
$2.5M
0.01%
#640 of 997new13F
Rockefeller Capital Management Family office
Rockefeller family
$482K
0.00%
#2106 of 4729-50.8%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

BRKR Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 152,000,000 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

439 filers153,372,427 shares$9.05B value100.90% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 20,237,425 $1.22B 13.45% 13.31% 2026-06-30
2 Orbis Allan Gray Ltd 17,940,076 $1.08B 11.92% 11.80% 2026-06-30
3 BlackRock, Inc. Custodian 11,407,332 $686.49M 7.58% 7.50% 2026-06-30
4 Pallas Capital Advisors LLC 9,483,978 $570.75M 6.30% 6.24% 2026-06-30
5 Vanguard Group Inc Custodian 10,259,824 $483.34M 5.34% 6.75% 2025-12-31
6 Vanguard Portfolio Management LLC 4,888,290 $294.18M 3.25% 3.22% 2026-06-30
7 Vanguard Capital Management LLC 4,859,252 $292.43M 3.23% 3.20% 2026-06-30
8 Sculptor Capital LP 4,625,000 $278.33M 3.07% 3.04% 2026-06-30
9 State Street Corp 4,017,673 $241.95M 2.67% 2.64% 2026-06-30
10 Franklin Resources, Inc. Custodian 3,229,337 $194.34M 2.15% 2.12% 2026-06-30
11 Sachem Head Capital Management LP 2,915,000 $175.42M 1.94% 1.92% 2026-06-30
12 EDMOND DE ROTHSCHILD HOLDING S.A. 2,823,178 $169.90M 1.88% 1.86% 2026-06-30
13 Dimensional Fund Advisors LP Custodian 2,610,051 $157.07M 1.73% 1.72% 2026-06-30
14 AQR Capital Management, LLC Custodian 2,512,706 $149.49M 1.65% 1.65% 2026-06-30
15 LONDON CO OF VIRGINIA 2,480,357 $149.25M 1.65% 1.63% 2026-06-30
16 T. Rowe Price Associates, Inc. 2,458,339 $147.94M 1.63% 1.62% 2026-06-30
17 Geode Capital Management, LLC Custodian 2,275,361 $136.96M 1.51% 1.50% 2026-06-30
18 First Trust Advisors LP 2,065,984 $124.33M 1.37% 1.36% 2026-06-30
19 Morgan Stanley Custodian 1,834,684 $110.41M 1.22% 1.21% 2026-06-30
20 Artisan Partners Limited Partnership 1,491,726 $89.77M 0.99% 0.98% 2026-06-30
21 BROWN ADVISORY INC 1,444,116 $86.91M 0.96% 0.95% 2026-06-30
22 SNYDER CAPITAL MANAGEMENT L P 1,428,327 $85.96M 0.95% 0.94% 2026-06-30
23 Alyeska Investment Group, L.P. 1,410,164 $84.86M 0.94% 0.93% 2026-06-30
24 Charles Schwab Investment Management, Inc. 1,399,125 $84.20M 0.93% 0.92% 2026-06-30
25 Goldman Sachs Group Inc Custodian 1,142,909 $68.78M 0.76% 0.75% 2026-06-30
10 filers$93.41M notional
# Filer Notional Value % of Total Period
1 Sculptor Capital LP $30.09M 32.21% 2026-06-30
2 Susquehanna International Group, LLP Custodian $23.31M 24.96% 2026-06-30
3 PEAK6 LLC $18.05M 19.33% 2026-06-30
4 NOMURA HOLDINGS INC $7.76M 8.30% 2026-06-30
5 Jane Street Group, LLC Custodian $6.84M 7.33% 2026-06-30
6 Citadel Advisors LLC Custodian $5.58M 5.97% 2026-06-30
7 Wolverine Trading, LLC Custodian $917.14K 0.98% 2025-09-30
8 Twin Tree Management, LP $511.53K 0.55% 2026-06-30
9 Walleye Capital LLC $330.99K 0.35% 2026-06-30
10 Chicago Partners Investment Group LLC $12.43K 0.01% 2026-06-30
8 filers$12.06M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $5.30M 43.90% 2026-06-30
2 Citadel Advisors LLC Custodian $3.39M 28.13% 2026-06-30
3 NOMURA HOLDINGS INC $1.49M 12.37% 2026-06-30
4 Jane Street Group, LLC Custodian $806.41K 6.68% 2026-06-30
5 Wolverine Trading, LLC Custodian $654.66K 5.43% 2025-09-30
6 Twin Tree Management, LP $264.79K 2.19% 2026-06-30
7 WOLVERINE ASSET MANAGEMENT LLC $102.31K 0.85% 2026-06-30
8 Walleye Capital LLC $54.16K 0.45% 2026-06-30

BRKR Insider Trading (Form 4)

Latest: 2026-09-16
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-16 Mark Munch EXEC VP&PRES BRUKER NANO INC. Mixed — $37.53 -$61.4K EDGAR
2026-08-18 Thomas Bures Chief Accounting Officer Award (A) +4,035 — EDGAR
2026-08-18 Burkhard Prause PRES. & CEO, BRUKER BEST Award (A) +3,303 — EDGAR
2026-08-18 Gerald N Herman EXECUTIVE VICE PRESIDENT, CFO Mixed +13,070 $57.70 -$157.2K EDGAR
2026-08-18 Wolfgang Pusch President BMID Group Mixed −353 $56.90 -$197.6K EDGAR
2026-08-18 Frank H Laukien PRESIDENT & CEO Mixed +24,703 $57.70 -$274.7K EDGAR
2026-08-18 Mark Munch EXEC VP&PRES BRUKER NANO INC. Mixed +11,459 $47.50 -$243.0K EDGAR
2026-08-18 Juergen Srega PRESIDENT CALID Award (A) +16,898 — EDGAR
2026-08-13 Frank H Laukien PRESIDENT & CEO Tax (F) −4,838 $57.02 -$275.9K EDGAR
2026-08-13 Gerald N Herman EXECUTIVE VICE PRESIDENT, CFO Tax (F) −1,410 $57.02 -$80.4K EDGAR
2026-08-13 Mark Munch EXEC VP&PRES BRUKER NANO INC. Tax (F) −1,619 $57.02 -$92.3K EDGAR
2026-08-11 Mark Munch EXEC VP&PRES BRUKER NANO INC. Tax (F) −3,477 $54.73 -$190.3K EDGAR
2026-08-11 Gerald N Herman EXECUTIVE VICE PRESIDENT, CFO Tax (F) −2,889 $54.71 -$158.1K EDGAR
2026-08-11 Frank H Laukien PRESIDENT & CEO Tax (F) −6,925 $55.33 -$383.1K EDGAR
2026-07-16 Mark Munch EXEC VP&PRES BRUKER NANO INC. Mixed — $41.22 -$76.1K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

BRKR Insider Holdings

17 insiders · @ $58.23
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Frank H Laukien PRESIDENT & CEO 38,583,531 $2.25B -$55.96M 134 2026-08-18
2 Juergen Srega PRESIDENT CALID 174,625 $10.17M -$18.11M 14 2026-08-18
3 Mark Munch EXEC VP&PRES BRUKER NANO INC. 136,806 $7.97M -$8.80M 48 2026-09-16
4 Gerald N Herman EXECUTIVE VICE PRESIDENT, CFO 111,354 $6.48M -$1.07M 16 2026-08-18
5 Richard A Packer Director 84,202 $4.90M -$1.90M 26 2025-02-19
6 William A Linton Director 58,723 $3.42M $134.0K 34 2025-04-24
7 Falko Busse PRESIDENT, BIOSPIN GROUP 48,171 $2.80M -$2.40M 9 2025-08-19
8 Bob Rosenthal Director 34,261 $2.00M -$295.7K 12 2025-02-19
9 John A Ornell Director 31,445 $1.83M $0 12 2025-05-14
10 Burkhard Prause PRES. & CEO, BRUKER BEST 28,461 $1.66M -$3.06M 15 2026-08-18
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

BRKR Board & Officers

As of SEC filings through Sep 16, 2026

Directors 11

Officers 8

10% owners 1

Changes in the last 10 years (18)
Jul 1, 2026Wolfgang Pusch became President BMID Group
Apr 1, 2026Thierry Bernard became a director
Feb 19, 2026The company announced the departure of Jack Phillips from the board in an SEC filing
Jan 1, 2026Jack Phillips became a director
Feb 18, 2025Laura Francis became a director
Jan 13, 2025Thomas Bures became Chief Accounting Officer
Aug 5, 2024The company announced the departure of Philip Ma from the board in an SEC filing
Aug 14, 2023Juergen Srega listed as President Calid (previously Group President Bruker CALID) in SEC filings
Aug 15, 2022Gerald N Herman listed as Executive Vice President, CFO (previously Vice President, CFO) in SEC filings
Aug 15, 2022Burkhard Prause listed as Pres. & CEO, Bruker Best (previously Pres. & CEO, Bruker EST) in SEC filings
Apr 1, 2022Philip Ma became a director
Mar 15, 2022The company announced the departure of Marc A Kastner from the board in an SEC filing
Sep 3, 2020Bonnie H Anderson became a director
Aug 13, 2018Gerald N Herman listed as Vice President, CFO (previously Vice President, Corp Contr.) in SEC filings
May 1, 2018Falko Busse became President, BioSpin Group
Feb 16, 2018Gerald N Herman became Vice President, Corp Contr.
May 22, 2017Adelene Q Perkins became a director
Feb 22, 2017Joerg C Laukien no longer listed as a 10% owner in SEC filings
Not reported recently (7)
  • Gilles Gerard Jean Martin · Last reported as a director in an SEC filing dated May 13, 2020
  • Anthony L Mattacchione · Last reported as Senior Vice President & CFO in an SEC filing dated Feb 22, 2018
  • Richard Kniss · Last reported as a director in an SEC filing dated Jan 9, 2018
  • Joerg C Laukien · Last reported as a director in an SEC filing dated Jan 9, 2018
  • Chris Van Ingen · Last reported as a director in an SEC filing dated Jun 15, 2017
  • Rene Lenggenhager · Last reported as President, BioSpin Group in an SEC filing dated Mar 1, 2017
  • Stephen W. Fesik · Last reported as a director in an SEC filing dated Jan 9, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

BRKR Proposed Insider Sales (Form 144)

Latest: 2026-09-15
Last 30d: 0 filings  ·  Last 90d: 3 filings · $419K notice value · 2 unique filers · 67% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: MARK R MUNCH (2, $221K) · WOLFGANG PUSCH (1, $198K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-09-15 MARK R MUNCH Officer 2,000 $105.7K 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-17 WOLFGANG PUSCH Officer 3,473 $197.6K 2026-08-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-14 MARK R MUNCH Officer 2,000 $115.2K 2026-08-14 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-07-15 MARK R MUNCH Officer 2,000 $120.5K 2026-07-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-15 MARK R MUNCH Officer 2,000 $109.5K 2026-06-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-15 MARK R MUNCH Officer 2,000 $87.8K 2026-05-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-04-15 MARK R MUNCH Officer 2,000 $79.8K 2026-04-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-13 MARK R MUNCH Officer 2,000 $70.9K 2026-03-13 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-02-13 MARK R MUNCH Officer 2,000 $73.9K 2026-02-13 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-01-15 MARK R MUNCH Officer 2,000 $98.4K 2026-01-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-21
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-21 0001193125-26-234630 EDGAR
2026-05-15 0001193125-26-226767 EDGAR
2026-05-06 0001193125-26-207498 EDGAR
2026-04-28 0001193125-26-187102 EDGAR
2026-04-10 0001193125-26-151220 EDGAR
2026-04-01 0001193125-26-135660 EDGAR
2026-02-20 0001193125-26-061500 EDGAR
2026-02-12 0001193125-26-047618 EDGAR
2026-01-12 0001193125-26-010106 EDGAR
2025-12-09 0001193125-25-312106 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-27 0001193125-26-082523 EDGAR
2025-03-03 0000950170-25-030897 EDGAR
2024-02-29 0000950170-24-023038 EDGAR
2023-03-01 0000950170-23-005251 EDGAR
2022-02-28 0001193125-22-056531 EDGAR
2021-03-01 0001104659-21-029938 EDGAR
2020-03-27 0001104659-20-039645 EDGAR
2019-03-01 0001047469-19-000839 EDGAR
2018-03-16 0001047469-18-001779 EDGAR
2017-03-01 0001047469-17-001114 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-05-07 0001193125-26-211889 EDGAR
2025-11-05 0001193125-25-267049 EDGAR
2025-08-06 0000950170-25-103333 EDGAR
2025-05-07 0000950170-25-065610 EDGAR
2024-11-07 0000950170-24-123298 EDGAR
2024-08-09 0000950170-24-094832 EDGAR
2024-05-10 0000950170-24-057736 EDGAR
2023-11-09 0000950170-23-062192 EDGAR
2023-08-09 0000950170-23-040491 EDGAR
2023-05-10 0000950170-23-020404 EDGAR
ETF Holders
123 ETFs hold BRKR
25 shown · $1.42B total exposure · 0.17% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IJH iShares Core S&P Mid-Cap ETF iShares (BlackRock) 0.19% $229.7M $122.3B 2026-10-23
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.01% $220.0M — 2026-09-30
3 VB Vanguard Morningstar Small-Cap ETF Vanguard 0.09% $155.5M — 2026-09-30
4 VBR Vanguard Morningstar Small-Cap Value ETF Vanguard 0.16% $101.2M — 2026-09-30
5 FBT First Trust NYSE® Arca® Biotechnology Index Fund First Trust 3.22% $95.8M $3.0B 2026-10-23
6 VXF Vanguard Extended Market ETF Vanguard 0.09% $81.2M — 2026-09-30
7 PFF iShares Preferred and Income Securities ETF iShares (BlackRock) 0.59% $69.7M $11.8B 2026-10-23
8 DFAS Dimensional US Small Cap ETF Dimensional 0.18% $61.4M — 2026-10-23
9 IBB iShares Biotechnology ETF iShares (BlackRock) 0.45% $48.6M $10.7B 2026-10-23
10 MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust SPDR (State Street) 0.19% $48.1M $25.6B 2026-10-23
11 SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF SPDR (State Street) 0.19% $34.8M $18.4B 2026-10-23
12 SCHA Schwab U.S. Small-Cap ETF Nport 0.14% $31.4M — 2026-05-31
13 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.03% $28.4M — 2026-10-23
14 IWR iShares Russell Mid-Cap ETF iShares (BlackRock) 0.05% $26.7M $57.3B 2026-10-23
15 KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF SPDR (State Street) 1.07% $26.6M $2.5B 2026-10-23
16 VHT Vanguard Health Care ETF Vanguard 0.10% $21.1M — 2026-09-30
17 IJK iShares S&P Mid-Cap 400 Growth ETF iShares (BlackRock) 0.20% $20.4M $10.3B 2026-10-23
18 FNDA Schwab Fundamental U.S. Small Company ETF Nport 0.20% $18.1M — 2026-05-31
19 SCHM Schwab U.S. Mid-Cap ETF Nport 0.12% $17.6M — 2026-05-31
20 PFFD Global X U.S. Preferred ETF Global X 0.90% $16.5M — 2026-10-26
21 IJJ iShares S&P Mid-Cap 400 Value ETF iShares (BlackRock) 0.18% $15.3M $8.6B 2026-10-23
22 IWD iShares Russell 1000 Value ETF iShares (BlackRock) 0.02% $14.3M $84.8B 2026-10-23
23 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.03% $13.0M — 2026-10-23
24 IVOO Vanguard S&P Mid-Cap 400 ETF Vanguard 0.21% $12.0M — 2026-09-30
25 IWS iShares Russell Mid-Cap Value ETF iShares (BlackRock) 0.06% $9.7M $15.7B 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-0.24
TTM Revenue
$3.46B
TTM Net Income
$-36.40M
TTM Op. Cash Flow
$140.30M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31$823.40M$3.50M$0.02$71.20M
Q4 '252025-12-31$977.20M$14.90M$0.10$229.80M
Q3 '252025-09-30$860.50M$-62.40M$-0.41$-33.20M
Q2 '252025-06-30$797.40M$7.60M$0.05$-127.50M
Q1 '252025-03-31$801.40M$17.40M$0.11$65.00M
Q4 '242024-12-31$979.60M$13.70M$0.09$190.00M
Q3 '242024-09-30$864.40M$40.90M$0.27$38.40M
Q2 '242024-06-30$800.70M$7.60M$0.05$1.10M
Q1 '242024-03-31$721.70M$50.90M$0.35$21.80M
Q4 '232023-12-31$854.50M$205.50M$1.40$205.50M
Q3 '232023-09-30$742.80M$88.10M$0.60$44.10M
Q2 '232023-06-30$681.90M$57.10M$0.39$13.00M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.59
P/S
2.56
EV/EBITDA
26.91
EV/Sales
3.00
ROE
-1.5%
ROA
-0.6%
Div Yield
0.62%
FCF Yield
1.59%
Debt/Equity
0.67
Current Ratio
—
Market Cap
$8.85B
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
12.41M
SI % of Float
11.15%
Days to Cover
5.09
Short Vol Ratio
25.4%
Free Float
111.30M
Float %
73.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-07